Secondary Cytoreduction Versus Chemotherapy Alone in the Treatment of Patients with Recurrent Ovarian Cancer: Is a Randomized Trial Worthwhile? Paolo SammartinoDaniele BiacchiMarialuisa Framarino Letter to the Editor 28 February 2013 Pages: 191 - 191
In Reply: Response to Sammartino et al. Philipp HarterFlorian HeitzAndreas du Bois Letter to the Editor 28 February 2013 Pages: 192 - 192
Provider Impact on Survival Outcomes in the Management of Malignant Disease Maurie Markman Invited Commentary 22 February 2013 Pages: 193 - 196
Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed? Keiichi FujiwaraAkira KurosakiKosei Hasegawa Invited Commentary 16 March 2013 Pages: 197 - 200
Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice? Susana BanerjeeMartin Gore Invited Commentary 27 March 2013 Pages: 201 - 203
Follow-Up of Epithelial Ovarian Cancer: Overdue For A Major Rethink Paul Hoskins Invited Commentary 13 March 2013 Pages: 204 - 206
The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion Michael BradshawAaron MansfieldTobias Peikert Hot Topic 10 April 2013 Pages: 207 - 216
Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer Sausan AbouharbPaul G. Corn Genitourinary Cancers (E Jonasch, Section Editor) 09 April 2013 Pages: 217 - 223
Novel Immunotherapies in GU Malignancies Alexandra DrakakiDavid F. McDermott Genitourinary Cancers (E Jonasch, Section Editor) 22 March 2013 Pages: 224 - 231
Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference? Yago Nieto Genitourinary Cancers (E Jonasch, Section Editor) 14 March 2013 Pages: 232 - 238
New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer Erin E. EzzellKuang S. ChangBenjamin J. George Genitourinary Cancers (E Jonasch, Section Editor) 27 February 2013 Pages: 239 - 248
Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem Viswanath Reddy BelumAlyssa FischerMario E. Lacouture Palliative Medicine (A Jatoi, Section Editor) 06 March 2013 Pages: 249 - 259
Clearing the Air: A Review of Our Current Understanding of “Chemo Fog” Erin O’FarrellJoyce MacKenzieBarbara Collins Palliative Medicine (A Jatoi, Section Editor) 13 March 2013 Pages: 260 - 269
Benefit and Harms of New Anti-Cancer Drugs Francisco E. Vera-BadilloMustafa Al-MubarakEitan Amir Palliative Medicine (A Jatoi, Section Editor) 23 February 2013 Pages: 270 - 275
Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists? Morgan TrammelMary RoedererHoward McLeod Palliative Medicine (A Jatoi, Section Editor) 21 March 2013 Pages: 276 - 285